Medical Policy
Closure Devices for Patent Foramen Ovale and Atrial Septal Defects

Table of Contents
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References
- Endnotes

Policy Number: 121
BCBSA Reference Number: 2.02.09
NCD/LCD: N/A

Related Policies
None

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Transcatheter closure of secundum atrial septal defects (ASD) may be considered MEDICALLY NECESSARY when using a device that has been FDA-approved for that purpose and used according to the labeled indications.

Transcatheter closure of a patent foramen ovale (PFO) may be considered MEDICALLY NECESSARY for the prevention of subsequent stroke in individuals with a history of cryptogenic stroke who have failed conventional drug therapy, (for example, warfarin), or who are not candidates for conventional drug therapy.¹

Transcatheter closure of a patent foramen ovale for the prevention of stroke is considered INVESTIGATIONAL when the criteria above are not met.¹

Prior Authorization Information
Pre-service approval is required for all inpatient services for all products.
See below for situations where prior authorization may be required or may not be required.
Yes indicates that prior authorization is required.
No indicates that prior authorization is not required.
N/A indicates that this service is primarily performed in an inpatient setting.

<table>
<thead>
<tr>
<th>Outpatient</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>N/A</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare HMO Blue&lt;sup&gt;SM&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
<tr>
<td>Medicare PPO Blue&lt;sup&gt;SM&lt;/sup&gt;</td>
<td>N/A</td>
</tr>
</tbody>
</table>

¹ Transcatheter closure of a patent foramen ovale for the prevention of stroke is considered INVESTIGATIONAL when the criteria above are not met.
CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

### CPT Codes

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93580</td>
<td>Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant</td>
</tr>
</tbody>
</table>

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT codes above if medical necessity criteria are met:

### ICD-9 Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-9-CM codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>745.5</td>
<td>Ostium secundum type atrial septal defect</td>
</tr>
</tbody>
</table>

### ICD-10 Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q21.1</td>
<td>Atrial septal defect</td>
</tr>
</tbody>
</table>

### Description

**PATENT FORAMEN OVALE**
The foramen ovale, a component of fetal cardiovascular circulation, consists of a communication between the right and left atrium that functions as a vascular bypass of the uninflated lungs. The ductus arteriosus is another feature of the fetal cardiovascular circulation, consisting of a connection between the pulmonary artery and the distal aorta. Before birth, the foramen ovale is held open by the large flow of blood into the left atrium from the inferior vena cava. Over a course of months after birth, an increase in left atrial pressure and a decrease in right atrial pressure result in permanent closure of the foramen ovale in most individuals. However, a patent foramen ovale (PFO) is a common finding in 25% of asymptomatic adults. In some epidemiologic studies, PFO has been associated with cryptogenic stroke, defined as an ischemic stroke occurring in the absence of potential cardiac, pulmonary, vascular, or neurologic sources. Studies have also shown an association between PFO and migraine headache. There has been interest in open surgery and transcatheter approaches to close the PFO in patients with a history of cryptogenic stroke to prevent recurrent stroke.

**ATRIAL SEPTAL DEFECTS**
Unlike PFO, which represents the postnatal persistence of normal fetal cardiovascular physiology, atrial septal defects (ASDs) represent an abnormality in the development of the heart that results in free communication between the atria. ASDs are categorized by their anatomy. Ostium secundum describes defects located midsceptally and are typically near the fossa ovalis. Ostium primum defects lie immediately...
adjacent to the atrioventricular valves and are within the spectrum of atrioventricular septal defects. Primum defects occur commonly in patients with Down syndrome. Sinus venous defects occur high in the atrial septum and are frequently associated with anomalies of the pulmonary veins.

Ostium secundum ASDs are the third most common form of congenital heart disorder and among the most common congenital cardiac malformations in adults, accounting for 30% to 40% of these patients older than age 40 years. The ASD often goes unnoticed for decades because the physical signs are subtle and the clinical sequelae are mild. However, virtually all patients who survive into their sixth decade are symptomatic; fewer than 50% of patients survive beyond age 40 to 50 years due to heart failure or pulmonary hypertension related to the left-to-right shunt. Symptoms related to ASD depend on the size of the defect and the relative diastolic filling properties of the left and right ventricles. Reduced left ventricular compliance and mitral stenosis will increase left-to-right shunting across the defect. Conditions that reduce right ventricular compliance and tricuspid stenosis will reduce left-to-right shunting or cause a right-to-left shunt. Symptoms of an ASD include exercise intolerance and dyspnea, atrial fibrillation, and, less commonly, signs of right heart failure. Patients with ASDs are also at risk for paradoxical emboli.

Treatment
Repair of ASDs is recommended for those with a pulmonary to systemic flow ratio (Qp:Qs) exceeding 1.5:1.0. Despite the success of surgical repair, there has been interest in developing a transcatheter-based approach to ASD repair to avoid the risks and morbidity of open heart surgery. A variety of devices have been researched. Technical challenges include minimizing the size of device so that smaller catheters can be used, developing techniques to properly center the device across the ASD, and ensuring that the device can be easily retrieved or repositioned, if necessary.

Individuals with ASDs and a history of cryptogenic stroke are typically treated with antiplatelet agents, given an absence of evidence that systemic anticoagulation is associated with outcome improvements.

Transcatheter Closure Devices
Several devices have been developed to treat PFO and ASDs via a transcatheter approach, including the CardioSEAL® STARFlex™ Septal Occlusion System, the Amplatzer® PFO Occluder, the Figulla® ASD Occluder (Occlutech GmbH, Jena, Germany), and the CeraFlex™ ASD Occluder (Lifetech Scientific, Shenzhen, China).

Transcatheter PFO and ASD occluders consist of a single or paired wire mesh discs that are covered or filled with polyester or polymer fabric that are placed over the septal defect. Over time, the occlusion system is epithelialized. ASD occluder devices consist of flexible mesh disks that are delivered via catheter to cover the ASD.

Summary
Patent foramen ovale (PFO) and atrial septal defects (ASDs) are relatively common congenital heart defects that can be associated with a range of symptoms. Depending on their size, ASDs may lead to left-to-right shunting and signs and symptoms of pulmonary overload. Repair of ASDs is indicated for patients with a significant degree of left-to-right shunting. PFOs may be asymptomatic but have been associated with higher rates of cryptogenic stroke. PFOs have also been investigated for a variety of other conditions, such as migraine. Transcatheter closure devices have been developed to repair PFO and ASDs. These devices are alternatives to open surgical repair for ASDs or treatment with antiplatelet and/or anticoagulant medications in patients with cryptogenic stroke and PFO.

For individuals who have PFO and cryptogenic stroke who receive PFO closure with a transcatheter device, the evidence includes 3 randomized controlled trials (RCTs) comparing device-based PFO closure with medical therapy, multiple nonrandomized comparative studies, and multiple systematic reviews and meta-analyses of these studies. Relevant outcomes are overall survival, morbid events, and treatment-related morbidity and mortality. None of the 3 trials reported statistically significant improvements on their main outcomes using intention-to-treat analysis. In all 3 trials, low numbers of outcome events in both groups limited the power to detect differences between groups. One trial showed a significant benefit for the closure group on per protocol analysis and another showed significant benefit
on secondary outcomes. Meta-analyses of these trials have also come to different conclusions, with some reporting statistically significant reductions in recurrent events on pooled analysis and others reporting a trend for benefit that was not statistically significant. A high-quality meta-analysis reported a significantly lower risk of recurrent ischemic stroke with device therapy, but a higher risk of atrial fibrillation. While these results suggest that a benefit might be present, the evidence is not definitive and the risk-benefit ratio of transcatheter PFO closure as an alternative to medical therapy is not well-defined. The evidence is insufficient to determine the effects of the technology on health outcomes.

Given the conflicting findings from multiple systematic reviews related to the use of PFO closure devices for stroke prevention, clinical input was obtained to address their use. Clinical input did not consistently support the use of PFO closure devices in patients with cryptogenic stroke or those with other indications.

For individuals who have PFO and migraines who receive PFO closure with a transcatheter device, the evidence includes 2 RCTs of PFO closure and multiple observational studies reporting on the association between PFO and migraine. Relevant outcomes are symptoms, quality of life, medication use, and treatment-related morbidity and mortality. The available sham-controlled randomized trial did not demonstrate significant improvements in migraine symptoms after PFO closure. A second RCT with blinded end point evaluation did not demonstrate improvements in migraine days after PFO closure, but likely it was underpowered. Nonrandomized studies have shown highly variable rates of migraine improvement after PFO closure. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have PFO and conditions associated with PFO other than cryptogenic stroke or migraine (eg, platypnea-orthodeoxia syndrome, myocardial infarction with normal coronary arteries, decompression illness, high-altitude pulmonary edema, obstructive sleep apnea) who receive PFO closure with a transcatheter device, the evidence includes small case series and case reports. Relevant outcomes are symptoms, change in disease status, morbid events, and treatment-related morbidity and mortality. The body of evidence only consists of small case series and case reports. Comparative studies are needed to evaluate outcomes in similar patient groups treated with and without PFO closure. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have ASD and evidence of left-to-right shunt or right ventricular overload who receive ASD closure with a transcatheter device, the evidence includes nonrandomized comparative studies and single-arm studies. Relevant outcomes are symptoms, change in disease status, and treatment-related morbidity and mortality. The available nonrandomized comparative studies and single-arm case series have shown rates of closure using transcatheter-based devices approaching the high success rates of surgery, which are supported by meta-analyses of these studies. The percutaneous approach has a low complication rate and avoids the morbidity and complications of open surgery. If the percutaneous approach is unsuccessful, ASD closure can be achieved using surgery. Because of the benefits of percutaneous closure over open surgery, it can be determined that transcatheter ASD closure improves outcomes in patients with an indication for ASD closure. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/2017</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>5/2016</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>9/2015</td>
<td>Added coding language.</td>
</tr>
<tr>
<td>5/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.</td>
</tr>
<tr>
<td>12/2013</td>
<td>New references from BCBSA National medical policy.</td>
</tr>
<tr>
<td>4/2013</td>
<td>New references from BCBSA National medical policy.</td>
</tr>
</tbody>
</table>
Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.

Reviewed - Medical Policy Group – Cardiology and Pulmonology. No changes to policy statements.

Review of BCBSA policy. No changes to policy statements.

Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.


Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:
- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

References


45. Rhodes JF, Jr., Goble J. Combined prospective United States clinical study data for the GORE(R) HELEX(R) septal occluder device. Catheter Cardiovasc Interv. May 1 2014;83(6):944-952. PMID 23674380


Endnotes

1 Based on expert opinion